Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice

Gene Therapy

Volumn 10, Issue 22, 2003, Pages 1891-1902

  Okada, N ^a   Masunaga, Y ^a   Okada, Y ^b   Mizuguchi, H ^c   Iiyama, S ^a   Mori, N ^a   Sasaki, A ^a   Nakagawa, S ^d   Mayumi, T ^d   Hayakawa, T ^c   Fujita, T ^a   Yamamoto, A ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Adenovirus vector; Dendritic cell; Fiber mutant; gp100; Immunotherapy; Melanoma

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; GLYCOPROTEIN GP 100;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG TARGETING; EFFECTOR CELL; FEMALE; GENE TARGETING; GENETIC MANIPULATION; GENETIC TRANSDUCTION; HELPER CELL; IMMUNE RESPONSE; IN VIVO STUDY; LUNG METASTASIS; LYMPHOCYTE FUNCTION; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VIRUS MUTANT;

ADENOVIRIDAE; ANIMALS; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MUTATION; NEOPLASM PROTEINS; OLIGOPEPTIDES; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0141996929     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302090     Document Type: Article

References (55)

1. Lanzavecchia A. Identifying strategies for immune intervention. Science 1993; 260: 937-944.
2. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995; 16: 117-121.
3. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol 1996; 24: 859-862.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
5. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Ann Rev Immunol 2000; 18: 245-273.
6. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-561.
7. + T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Int J Cancer 1999; 83: 532-540.
8. Sloan JM et al. MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Ther 2002; 9: 946-950.
9. Herrera OB, Brett S, Lechler RI. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design. Vaccine 2002; 21: 231-242.
10. Wan Y et al. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999; 198: 131-138.
11. Kaplan JM et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding enclogenous tumor-associated antigens. J Immunol 1999; 163: 699-707.
12. + T cell-dependent mechanism. Gene Therapy 2001; 8: 1255-1263.
13. Tillman BW et al. T. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD 40-targeted adenoviral vector. J Immunol 1999; 162: 6378-6383.
14. Asada-Mikami R et al. Efficient gene transduction by RGD-fiber modified recombinant adenovirus into dendritic cells. Jpn J Cancer Res 2001; 92: 321-327.
15. Okada N et al. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem Biophys Res Commun 2001; 282: 173-179.
16. Okada N et al. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther 2003; 10: 421-431.
17. Dmitriev I et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
18. Okada N et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61: 7913-7919.
19. Kawakami Y et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458-6462.
20. Bloom MB et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185: 453-459.
21. Coulie PG et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180: 35-42.
22. Kawakami Yet al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91: 3515-3519.
23. Robbins PF et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy, Cancer Res 1994; 54: 3124-3126.
24. Rosenberg SA et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-327.
25. Nestle FO et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
26. Perricone MA et al. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol Ther 2000; 1: 275-284.
27. Zhai Y et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 1997; 20: 15-25.
28. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 1996; 183: 1287-1292.
29. Lutz MB et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
30. Inaba K et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176: 1693-1702.
31. Bender A et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196: 121-135.
32. Reeves ME et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996; 56: 5672-5677.
33. Metharom P, Ellem KA, Schmidt C, Wei MQ. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum Gene Ther 2001; 12: 2203-2213.
34. Esslinger C, Romero P, MacDonald HR. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum Gene Ther 2002; 13: 1091-1100.
35. Arthur JF et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25.
36. + hematopoietic progenitor cells. Cancer Immunol Immunother 1999; 48: 118-122.
37. Lappin MB et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 1999; 98: 181-188.
38. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000; 11: 797-806.
39. Van Tendeloo VF, Van Broeckhoven C, Berneman ZN. Genebased cancer vaccines: an ex vivo approach. Leukemia 2001; 15: 545-558.
40. Sarantou T et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997; 57: 1371-1376.
41. Zhai Y et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART 1 or gp100 for cancer therapy. J Immunol 1996; 156: 700-710.
42. Rea D et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001; 166: 5236-5244.
43. Prehn RT. The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in keratoacanthoma. Cancer Res 1996; 56: 937-940.
44. Wildemore IV JK et al. Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study. Ann Plast Surg 2001; 46: 488-494.
45. Fernandez NC et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5: 405-411.
46. Amakata Y et al. Mechanism of NK cell activation induced by coculture with dendritic cells derived from peripheral blood monocytes. Clin Exp Immunol 2001; 124: 214-222.
47. Miller G et al. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002; 62: 5260-5266.
48. Wan Y et al. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res 2000; 60: 3247-3253.
49. Curiel-Lewandrowski C et al. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999; 163: 174-183.
50. Melero I et al. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Therapy 1999; 6: 1779-1784.
51. + T cells. Nat Med 2000; 6: 1154-1159.
52. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998; 9: 2577-2583.
53. Mizuguchi H, Kay MA. A simple method for constructing E1-and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999; 10: 2013-2017.
54. Mizuguchi H et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Therapy 2001; 8: 730-735.
55. Okada N et al. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 2001; 84: 1564-1570.